DK2640743T3 - PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS - Google Patents
PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS Download PDFInfo
- Publication number
- DK2640743T3 DK2640743T3 DK11801886.0T DK11801886T DK2640743T3 DK 2640743 T3 DK2640743 T3 DK 2640743T3 DK 11801886 T DK11801886 T DK 11801886T DK 2640743 T3 DK2640743 T3 DK 2640743T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- polyclonal
- cells
- cell population
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41422510P | 2010-11-16 | 2010-11-16 | |
| PCT/US2011/061092 WO2012068317A2 (en) | 2010-11-16 | 2011-11-16 | Methods for producing recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2640743T3 true DK2640743T3 (en) | 2017-01-23 |
Family
ID=45406837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11801886.0T DK2640743T3 (en) | 2010-11-16 | 2011-11-16 | PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8617881B2 (enExample) |
| EP (1) | EP2640743B1 (enExample) |
| JP (1) | JP6092782B2 (enExample) |
| AU (1) | AU2011329872B2 (enExample) |
| CA (1) | CA2817751C (enExample) |
| DK (1) | DK2640743T3 (enExample) |
| WO (1) | WO2012068317A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| TWI554608B (zh) * | 2015-03-27 | 2016-10-21 | Univ China Medical | A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3810649A1 (en) | 2018-06-22 | 2021-04-28 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| AU2022291273A1 (en) * | 2021-06-10 | 2024-01-25 | Janssen Biotech, Inc. | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5686120A (en) | 1995-05-22 | 1997-11-11 | Wisconsin Alumni Research Foundation | Pre-mRNA processing enhancer and method for intron-independent gene expression |
| BR9808584A (pt) | 1997-03-14 | 2000-05-23 | Idec Pharma Corp | Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| AU6364800A (en) | 1999-07-23 | 2001-02-13 | Regents Of The University Of California, The | Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system |
| AU2001271614B2 (en) | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
| CA2413156C (en) | 2000-07-03 | 2009-08-18 | Gala Design, Inc. | Expression vectors |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| CA2512647C (en) * | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| ES2785223T3 (es) * | 2006-06-21 | 2020-10-06 | Uniqure Ip Bv | Células de insecto para la producción de vectores de AAV |
| HRP20100640T1 (hr) * | 2007-05-25 | 2010-12-31 | Symphogen A/S | Postupak proizvodnje rekombinantnog poliklonskog proteina |
| CA2722348A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
-
2011
- 2011-11-16 DK DK11801886.0T patent/DK2640743T3/en active
- 2011-11-16 WO PCT/US2011/061092 patent/WO2012068317A2/en not_active Ceased
- 2011-11-16 CA CA2817751A patent/CA2817751C/en active Active
- 2011-11-16 AU AU2011329872A patent/AU2011329872B2/en active Active
- 2011-11-16 JP JP2013539992A patent/JP6092782B2/ja not_active Expired - Fee Related
- 2011-11-16 EP EP11801886.0A patent/EP2640743B1/en active Active
-
2012
- 2012-06-13 US US13/495,993 patent/US8617881B2/en active Active
-
2013
- 2013-09-26 US US14/037,833 patent/US9447174B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8617881B2 (en) | 2013-12-31 |
| CA2817751A1 (en) | 2012-05-24 |
| WO2012068317A3 (en) | 2012-08-16 |
| JP2014501505A (ja) | 2014-01-23 |
| US20140127743A1 (en) | 2014-05-08 |
| AU2011329872A1 (en) | 2013-06-06 |
| US9447174B2 (en) | 2016-09-20 |
| AU2011329872B2 (en) | 2017-04-13 |
| EP2640743A2 (en) | 2013-09-25 |
| WO2012068317A2 (en) | 2012-05-24 |
| CA2817751C (en) | 2019-04-30 |
| US20120302464A1 (en) | 2012-11-29 |
| EP2640743B1 (en) | 2016-10-05 |
| JP6092782B2 (ja) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2640743B1 (en) | Methods for producing recombinant proteins | |
| Gardner et al. | AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges | |
| Gardner et al. | AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges | |
| Martinez-Navio et al. | Long-term delivery of an anti-SIV monoclonal antibody with AAV | |
| US20230340085A1 (en) | Lentiviral vector expressing membrane-anchored or secreted antibody | |
| Fuchs et al. | Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in rhesus monkeys | |
| van den Berg et al. | AAV-mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 region | |
| Badamchi-Zadeh et al. | Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice | |
| US12209113B2 (en) | Methods and compositions for protection against lentiviral infections | |
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| Phelps et al. | Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis | |
| CN112442514B (zh) | 慢病毒包装载体系统、慢病毒及其构建方法、试剂盒 | |
| US20110305670A1 (en) | Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection | |
| JP7848138B2 (ja) | 改変型上皮成長因子受容体及び細胞追跡におけるその使用 | |
| WO2022188689A1 (zh) | 使用双重病毒载体系统递送抗体 | |
| Schnepp et al. | Vector-mediated antibody gene transfer for infectious diseases | |
| WO2024243073A1 (en) | Anti-codon engineered suppressor transfer rnas | |
| CN117363656A (zh) | 核酸构建体及其用途 | |
| US20250375536A1 (en) | Vector | |
| CN113039270A (zh) | 用于蛋白质制造的载体 | |
| US20250242018A1 (en) | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration | |
| WO2025133635A1 (en) | Therapies for preventing or treating inflammatory eye disease | |
| Chiyyeadu et al. | Therapeutic antibody delivery: vector tools to boost efficacy and affordability | |
| WO2025184603A2 (en) | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration | |
| HK40096820A (zh) | 核酸构建体及其用途 |